Skip to main content
Keeps Biopharma Inc. logo

Keeps Biopharma Inc. — Investor Relations & Filings

Ticker · 256940 ISIN · KR7256940008 KO Manufacturing
Open in API
Filings indexed 290 across all filing types
Latest filing 2026-03-13 AGM Information
Country KR South Korea
Listing KO 256940

About Keeps Biopharma Inc.

http://kpscorp.co.kr/

Keeps Biopharma Inc. is a company with operations in both manufacturing and biopharmaceuticals. Its manufacturing activities include the production of equipment for semiconductors and flat panel displays, such as organic light-emitting diodes (OLEDs), as well as cleanroom consumables. Concurrently, the company is expanding its biopharmaceutical business through research and development. Its strategic focus is on building a therapeutic pipeline centered on oncology and metabolic diseases, which includes the development of novel anticancer drugs and combination therapies.

Recent filings

Filing Released Lang Actions
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a formal regulatory filing submitted to the exchange regarding the scheduling of a General Meeting of Shareholders on a 'concentrated date' (a date when many companies hold their meetings). It explains the operational reasons for this scheduling conflict. Since it is a regulatory notification regarding meeting logistics rather than the meeting materials themselves, proxy statements, or voting results, it falls under the general regulatory filing category.
2026-03-13 Korean
투자판단관련주요경영사항(임상시험계획승인신청) (Idtrexed(CT900) 기반 항암 치료제의 제2상 임상시험계획 승인신청(IND))
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a Korean company (Kips Pharma) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the submission of an Investigational New Drug (IND) application for a Phase 2 clinical trial. This type of disclosure is a standard regulatory requirement for publicly traded companies to inform shareholders of significant operational developments. Since it does not fit into specific categories like financial reports, dividends, or board changes, and is a formal regulatory disclosure, it falls under the 'Regulatory Filings' category.
2026-03-10 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as a 'Section 6.1' report) used to disclose insider shareholdings and changes in ownership by company directors or major shareholders. This aligns perfectly with the 'Director's Dealing' (DIRS) category, which covers personal share transactions and ownership reporting by company insiders.
2026-03-03 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and collateral agreements (stock-backed loans) of a major shareholder (Thummim Co., Ltd.) in the issuer (Keeps Biopharma). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2026-01-26 Korean
전환가액의조정
Capital/Financing Update Classification · 95% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price of convertible bonds (전환가액의 조정) for the company 'Kips Pharma'. It details the change in conversion price, the number of convertible shares, the reason for the adjustment (market price decline), and the legal basis for the adjustment. This type of filing relates to changes in capital structure and financing instruments, which falls under the 'Capital/Financing Update' category.
2026-01-19 Korean
[기재정정]주요사항보고서(유형자산양수결정)
Regulatory Filings Classification · 95% confidence The document is a correction notice (정정신고) related to a previously submitted major event report (주요사항보고서) concerning the decision to acquire tangible assets (유형자산 양수 결정). It details changes in payment dates and other transaction specifics. The document is relatively short (3051 characters) and serves as an update or correction to a prior disclosure rather than a full report. It is a regulatory announcement about a transaction event, not a full financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and corrections that do not fit other specific categories.
2025-10-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.